4 results match your criteria: "China. cui.yuehong@zs-hospital.sh.cn.[Affiliation]"
Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.
Nat Commun
October 2024
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Article Synopsis
- * The OASIS phase II trial evaluated nivolumab and anlotinib hydrochloride in 48 patients, achieving a primary overall response rate of 29.2% and a disease control rate of 64.6%, with median overall survival of 11.1 months.
- * Findings suggest that gut bacteria balance and certain immune signatures may be linked to better outcomes, highlighting the role of individual immune profiles in treatment effectiveness.
Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
BMC Gastroenterol
June 2022
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Background: To compare the prognosis of first-line systemic chemotherapy of AS (Albumin-bound paclitaxel and S-1) versus SOX (S-1 and oxaliplatin) regimen in Chinese gastric cancer patients with peritoneal metastasis.
Methods: This was a real-world study of gastric cancer patients with peritoneal metastasis who have been treated with AS or SOX regimen as first-line chemotherapy. Patients were matched by the method of propensity score matching (PSM).
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Mol Cancer
February 2022
Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Article Synopsis
- The CRISPR system provides a way for prokaryotes to fight off viruses and plasmids, leading to the creation of the CRISPR/Cas9 genome editing tool, known for its precision and efficiency in genetic manipulation.
- This technology has revolutionized cancer research by helping scientists study cancer-related genes, create animal models, and identify drug targets, thereby deepening our understanding of cancer genomics.
- The review covers the principles of CRISPR/Cas9, new editing methods, advancements in cancer-related screening, delivery systems for the technology, and its potential to improve adoptive T cell therapy and minimize side effects.
Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.
J Exp Clin Cancer Res
January 2022
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Background: Chemoresistance is a main obstacle in gastric cancer (GC) treatment, but its molecular mechanism still needs to be elucidated. Here, we aim to reveal the underlying mechanisms of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) resistance in GC.
Methods: We performed RNA sequencing (RNA-seq) on samples from patients who were resistant or sensitive to nab-paclitaxel, and identified Zinc Finger Protein 64 (ZFP64) as critical for nab-paclitaxel resistance in GC.